Background Image
Previous Page  152 / 156 Next Page
Information
Show Menu
Previous Page 152 / 156 Next Page
Page Background

150

http://www.DGS-PraxisLeitlinien.de

Nr.

Nachweis

331

van Hooft JE, Dijkgraaf MG, Timmer R, Siersema PD, Fockens P. Independent predictors

of survival in patients with incurable malignant gastric outlet obstruction: a multicenter

prospective observational study. Scand J Gastroenterol 2010; 45(10): 1217-1222.

332

Vasisht N, Gever LN, Tagarro I, Finn AL. Evaluation of the single- and multiple-dose

pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers. J Clin

Pharmacol 2010; 50(7): 785-791.

333

Vasisht N, Gever LN, Tagarro I, Finn AL. Formulation selection and pharmacokinetic com-

parison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a rando-

mized, open-label, single-dose, crossover study. Clin Drug Investig 2009; 29(10): 647-654.

334

Vissers D, Stam W, Nolte T, Lenre M, Jansen J. Efficacy of intranasal fentanyl spray versus

other opioids for breakthrough pain in cancer. Curr Med Res Opin 2010; 26(5): 1037-

1045.

335

Voaklander DC, Rowe BH, Dryden DM, Pahal J, Saar P, Kelly KD. Medical illness, medi-

cation use and suicide in seniors: a population-based case-control study. J Epidemiol

Community Health 2008; 62(2): 138-146.

336

WALDVOGEL H. H. Analgetika, Antinozizeptiva, Adjuvantien (Handbuch für die Schmerz-

medizin). Springer-Verlag Berlin, Heidelberg, New York 2. Auflage, 2001;

337

Wallace M, Moulin DE, Rauck RL, Khanna S, Tudor IC, Skowronski R, Thipphawong J. Long-

term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic

pain. J Opioid Manag 2009; 5(2): 97-105.

338

Wallace M, Rauck RL, Moulin D, Thipphawong J, Khanna S, Tudor IC. Conversion from

standard opioid therapy to once-daily oral extended-release hydromorphone in patients

with chronic cancer pain. J Int Med Res 2008; 36(2): 343-352.

339

Wang G, Zhang H, He F, Fang X. Effect of the CYP2D6*10 C188T polymorphism on post-

operative tramadol analgesia in a Chinese population. Eur J Clin Pharmacol 2006; 62(11):

927-931.

340

Wang JJ. A survey of cancer pain status in Shanghai. Oncology 2008; 74 Suppl 1: 13-18.

341

Wang T, Tian FZ, Cai ZH, Li X, Cheng T, Shi L, Cheng Q. Ultrasonic interventional analgesia

in pancreatic carcinoma with chemical destruction of celiac ganglion. World J Gastroente-

rol 2006; 12(20): 3288-3291.

342

Wang ZY, Wang CQ, Yang JJ, Sun J, Huang YH, Tang QF, Qian YN. Which has the least

immunity depression during postoperative analgesia--morphine, tramadol, or tramadol

with lornoxicam? Clin Chim Acta 2006; 369(1): 40-45.

343

Watanabe S, Pereira J, Tarumi Y, Hanson J, Bruera E. A randomized double-blind crossover

comparison of continuous and intermittent subcutaneous administration of opioid for

cancer pain. J Palliat Med 2008; 11(4): 570-574.

344

Watson M, Lucas C, Hoy A, Wells J. Oxford Handbook of Palliative Care. Oxford, New York,

Oxford University Press, second Edition 2009;

Literaturverzeichnis